FDA Aims To Rebuild Its Science Reputation, Plans New Projects
This article was originally published in The Pink Sheet Daily
Executive Summary
Seven priority areas include rapid detection of contaminants, adverse event detection and analysis, biomarkers, and clinical trial design and analysis.